BioMarin Pharmaceuticals BMRN Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's change in AR?
- BioMarin Pharmaceuticals (BMRN) reported change in AR of $7.16M in Q1 2026.
- How has BioMarin Pharmaceuticals's change in AR changed year-over-year?
- BioMarin Pharmaceuticals's change in AR decreased by 87.6% year-over-year, from $57.59M to $7.16M.
- What does change in AR mean?
- The change in money owed to the company by customers.
- How do you interpret change in AR?
- An increase consumes cash, while a decrease releases cash; sustained increases may signal credit risk or aggressive revenue recognition.
- How does change in AR compare across companies?
- Standard metric across all industries; peers with similar business models should show comparable days sales outstanding.